Acquisitions, Topline Results, New Board Members, Events, and Product Milestones - Research Report on Johnson & Johnson, Sanofi,

    Acquisitions, Topline Results, New Board Members, Events, and Product
Milestones - Research Report on Johnson & Johnson, Sanofi, Lilly, AbbVie, and
                                   Novartis

PR Newswire

NEW YORK, September 2, 2013

NEW YORK, September 2, 2013 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.

Today, Investors' Reports announced new research reports highlighting Johnson
& Johnson (NYSE: JNJ), Sanofi (NYSE: SNY), Eli Lilly and Company (NYSE: LLY),
AbbVie Inc. (NYSE: ABBV), and Novartis AG (NYSE: NVS). Today's readers may
access these reports free of charge - including full price targets, industry
analysis and analyst ratings - via the links below.

Johnson & Johnson Research Report

On August 19, 2013, Johnson & Johnson announced that it has completed the
acquisition of Aragon Pharmaceuticals, Inc. (Aragon). Johnson & Johnson
reported that Aragon is a privately-held pharmaceutical discovery and
development company focused on drugs to treat hormonally-driven cancers. The
Company also stated that Janssen Research & Development, LLC, one of the
Janssen Pharmaceutical Companies of Johnson & Johnson, will manage the
development of compounds from Aragon's androgen receptor antagonist program,
including ARN-509, its lead androgen receptor signaling inhibitor. The Full
Research Report on Johnson & Johnson - including full detailed breakdown,
analyst ratings and price targets - is available to download free of charge
at: [http://www.InvestorsReports.com/report/2013-08-29/JNJ]

--

Sanofi Research Report

On August 26, 2013, Sanofi's vaccine division Sanofi Pasteur reported topline
results of a large-scale, multi-center efficacy trial showing a superior
clinical benefit of Fluzone High-Dose (Influenza Virus Vaccine) compared with
the standard dose of Fluzone vaccine in preventing influenza among patients
aged 65 years and above. David P. Greenberg, M.D., Vice President of US
Scientific and Medical Affairs at Sanofi Pasteur, stated, "This efficacy trial
complements the previous evidence of superior immune responses for Fluzone
High-Dose vaccine compared to Fluzone vaccine and reaffirms the Phase III
safety data in this population that were the basis for FDA licensure of
Fluzone High-Dose vaccine in 2009." The Full Research Report on Sanofi -
including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:
[http://www.InvestorsReports.com/report/2013-08-29/SNY]

--

Eli Lilly and Company Research Report

On August 28, 2013, Eli Lilly and Company (Lilly) announced the election of
Marschall S. Runge, M.D., Ph.D., as a member of its Board of Directors. Lilly
reported that Runge will assume his position on September 1, 2013. John
Lechleiter, Ph.D., Chairman, President, and CEO of Lilly, commented, "Dr.
Runge brings to the Lilly board a broad background in health care, with
extensive experience as a practicing physician, clinical researcher, and dean
of a major academic medical institution. His appreciation of the importance of
scientific research, coupled with his first-hand experience in patient care,
will help Lilly deliver on its commitment to discover and develop innovative
medicines that make a difference for patients in need." The Full Research
Report on Eli Lilly and Company - including full detailed breakdown, analyst
ratings and price targets - is available to download free of charge at:
[http://www.InvestorsReports.com/report/2013-08-29/LLY]

--

AbbVie Inc. Research Report

On August 27, 2013, AbbVie Inc. (AbbVie) announced that Richard A. Gonzalez,
Chairman and CEO, and Scott Brun, M.D., Vice President of Pharmaceutical
Development, will participate in the upcoming Morgan Stanley Global Healthcare
Conference. According to the Company, the event will be held on Tuesday,
September 10, 2013. AbbVie reported that Gonzalez and Brun will participate in
the question and answer session at 11:55 a.m. Central Time. The Company added
that the live audio webcast can be accessed through its Investor Relations
website. The Full Research Report on AbbVie Inc. - including full detailed
breakdown, analyst ratings and price targets - is available to download free
of charge at: [http://www.InvestorsReports.com/report/2013-08-29/ABBV]

--

Novartis AG Research Report

On August 20, 2013, Novartis AG (Novartis) announced that its BYM338
(bimagrumab) for sporadic inclusion body myositis (sIBM) has received a
breakthrough therapy designation from the US Food and Drug Administration
(FDA). Timothy Wright, M.D., Global Head of Development at Novartis
Pharmaceuticals, said, "BYM338 is the third example this year of Novartis'
leadership in bringing breakthrough therapies to patients reinforcing our
commitment to innovation addressing significant unmet medical needs and
enhancing the lives of patients." Wright added, "With no effective therapies
currently available for sIBM, bimagrumab has the potential to be the first
real option for patients with this condition." The Full Research Report on
Novartis AG - including full detailed breakdown, analyst ratings and price
targets - is available to download free of charge at:
[http://www.InvestorsReports.com/report/2013-08-29/NVS]

----

EDITOR NOTES:

1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by a CFA. However, we are only human and are prone to
    make mistakes. If you notice any errors or omissions, please notify us
    below.
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
5.For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider has, through Chartered Financial
Analysts, only reviewed the information provided by Equity News Network in
this article or report according to the Procedures outlined by Equity News
Network. Equity News Network is not entitled to veto or interfere in the
application of such procedures by the outsourced provider to the articles,
documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

http://www.InvestorsReports.com

SOURCE Investors' Reports

Contact: Kristi Saunders, +1-315-982-6420 (North America)
 
Press spacebar to pause and continue. Press esc to stop.